FIGURE

Fig. 6

ID

ZDB-FIG-230717-100

Publication

Quadri et al., 2023 - CD271 activation prevents low to high-risk progression of cutaneous squamous cell carcinoma and improves therapy outcomes

Other Figures

All Figure Page

Back to All Figure Page

Fig. 6

Effects of CD271 activation on cSCC spheroid viability and invasion a Cell viability (MTT assay) and b total area of SCC13 spheroids (n≥6) after β-Amyloid (40 μM and 60 μM) treatment as compared to control (PBS). c Left panel: Propidium Iodide (PI) staining (red)/brightfield on mock vs CD271-overexpressing SCC13 spheroids after β-Amyloid treatment as compared to control (PBS) at 48 h. Right: Bar chart representing PI-stained area (Pixel) (n = 3). Scale bar = 50 μm dNGFR, BIRC5 and CXCL8 mRNA levels (n = 8). e Left panel: Representative images of SCC13-derived implanted spheroid treated with β-Amyloid or PBS (control) and monitored for 2 weeks (scale bar = 50 μm). Middle panel: total invasion area. Right panel: percentage of fragmentation. f Left panel: PI staining/brightfield of CD271 and mock SCC13 spheroids treated with K252 (200 nM) or DMSO at 48 h. Right panel: Quantification of the PI staining/Total area ratio. Scale bar = 50 μm g Total area of SCC13 spheroids treated with TrkA/Fc (2 µg/ml), βAmyloid (40 μM) or the combinations TrkA/FC/βAmyloid (n = 3). Results are shown as mean ± SD of three independent experiments. Statistical analysis was performed using the two-way ANOVA and multiparametric T-test. *0.01 < p < 0.05, **0.001 < p < 0.01, ***0.0001 < p < 0.001, ****p < 0.0001

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Exp. Clin. Cancer Res.